Pfizer Pharmaceuticals (PFE) is currently funding a study to validate the ability of the Project:EVO™ platform to serve as a biomarker or cognitive endpoint for individuals at risk of developing Alzheimer's disease. We believe that this innovative study is the first in which a pharmaceutical company is using a video game to detect a major disease. The study is currently underway.
In 2013, Shire Pharmaceuticals' (SHPG) Strategic Investment group made a direct investment in Akili. Shire is a market-leader in ADHD medications, and has deep experience in ADHD clinical trials. In addition to the monetary investment, Akili and Shire have worked closely together to structure and launch Akili's first clinical study of the Project:EVO™platform in pediatric ADHD.
M Ventures joined Akili’s Series B financing in 2016 as an equity investor. M Ventures (known as Merck Ventures BV outside of the United States and Canada) is the strategic, corporate venture capital arm of Merck KGaA, Germany. Merck KGaA is a leading science and technology company for innovative and top-quality high-tech products in healthcare, life sciences and performance materials. The portfolio includes prescription medications for cancer, multiple sclerosis, and cardiovascular disorders, among many other products.
Amgen Ventures joined Akili’s Series B financing in 2016 as an equity investor. Amgen Ventures is the strategic ventures capital arm of Amgen and provides emerging innovative companies with financial and other resources to develop pioneering discoveries to treat grievous human illness. Amgen has a robust product offering and pipeline in oncology, inflammation, and cardiovascular disease.
Autism Speaks, through its not-for-profit investment affiliate DELSIA, entered into a clinical collaboration agreement in early 2015 to support a clinical trial of the Project:EVO™platform in children with autism and co-occurring attention deficits. The trial will be a blinded, randomized, placebo-controlled study that will look to measure cognitive and symptom improvement over 1 month of device play. Recruitment will begin in late 2016.
Additionally, Akili is in the process of licensing and accelerating product development of the very newest published and as-yet-unpublished neuroscience findings that could address major medical indications.
If you have a research program on a patient population with cognitive deficits, or new science that you would like to develop into engaging medical products, please contact Akili at email@example.com